| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IOX2 | GDSC1000 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |